Erytech Pharma, which is developing treatments for rare cancers and orphan diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company is listed on the Euronext Paris under the symbol ERYP with a market cap of €284 million.
The France-based company was founded in 2004 and plans to list on the Nasdaq under the symbol ERYP. Erytech Pharma filed confidentially on July 27, 2015. Jefferies, Cowen & Company and Oddo et Cie are the joint bookrunners on the deal. No pricing terms were disclosed.
